Eisai Preps Eritoran Phase III Sepsis Trial Based On Phase II Cut In Mortality

Eisai will commence a Phase III study of eritoran (E5564) for severe sepsis by the first quarter of 2006 after a Phase II trial showed a 6.4% mortality reduction versus placebo at 28 days, the firm said Aug. 29